Serial serum soluble stromelysirn-2 testing to assess prognosis in elderly patients with acute heart failure

Abstract

Objective To investigate the predicting value of serial serum human stromelysin-2(ST2)testing on prognosis in elderly patients with acute heart failure(AHF). Methods 75 AHF patients aged 60 to 90 were selected in our study who were in Beijing Hospital during 2013.1~2014.8, blood sampling of serum ST2 took place at admission and 72-96 h later.Moreover, 38 healthy people aged 70 to 80 were chosen as control group.Follow-up was performed 1 year after acute attack.We defined the end of observation as recurrence of heart failure or any cause of death.The data was analyzed by SPSS19.0. Results Among 55 AHF patients, sST2 level was higher in patients with endpoint events than those without it on the two moment(P=0.000). And we found that the change in sST2 was higher in patients with endpoint events than those without it(P=0.023); and the percentage change in sST2 was also significantly different(P=0.033). Receiver operator curve analysis of the change in sST2 from baseline to 72-96 h later was strongly reflective of prognosis with area under the curve(AUC) of 0.696(P=0.013). And the change in sST2 Combined with the sST2 level at admission to predict the prognosis of AHF, the result would be more exciting, the area under the receiver operating characteristic(ROC)curve is 0.861(P<0.001). The endpoint event rate of the patients whose level of sST2 at admission was below 1408 ng/L and the change level in sST2 below 101 ng/L was 21.4%(3/14), while the data in patients whose level of sST2 at admission is above 1 408 ng/L and the change level in sST2 above 100 ng/L was 85.7%(12/14). Conclusions in elderly patients of AHF, sST2 elevate markedly.The result shows that the level of sST2 may be used to evaluate AHF prognosis.And the change in sST2 are able to predict the prognosis of AHF.Compared with NT-proBNP, serial sST2 testing appears to be a promising candidate for monitoring these patients. Key words: Receptors, interleukin; Heart failure; Prognosis